A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...

The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...

A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...

Cosmo Pharmaceuticals says it plans to file for FDA approval of its androgenetic alopecia (AGA) candidate clascoterone 5% ...

Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat. Traditional therapies targeting androgen receptor (AR) signaling have limited ...

Triple-negative breast cancer (TNBC), particularly the luminal androgen receptor (LAR) subtype, presents significant ...

Automated Portal-Enabled Elicitation of Health-Related Patient Values in Solid Tumor Oncology: Feasibility and Patient Characteristics Associated With Patient Response The following represents ...

The trial is evaluating VIR-5500 with an androgen receptor pathway inhibitor in early-line mCRPC and mHSPC.

Androgen is a male sex steroid hormone that exerts important physiological functions leading to masculine characteristics, maturation of reproductive systems, and bone metabolism. The major ...